A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells.
The poor selectivity of photosensitizers for tumor tissue remains a drawback in photodynamic therapy (PDT) and could be improved by adapted formulations. The cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl)chlorin (mTHPC) encapsulated in submicronic colloidal carriers have been studied in macrophage-like J774 cells and HT 29 human adenocarcinoma cells. Nanocapsules with an external layer made of poly(D,L lactic acid) (PLA NCs), PLA grafted with polyethylene glycol (PLA-PEG NCs), PLA coated with poloxamer 188 (polox PLA NCs) and oil/water nanoemulsion (NE) have been examined. The cellular uptake by J774, as determined by microspectroflorimetry, is reduced with mTHPC encapsulated into surface-modified NCs--PLA-PEG and polox PLA--compared with naked PLA, indicating a possible limitation of the clearance of such carriers by the reticuloendothelial system. Encapsulation also modifies the interaction between mTHPC and HT29 cells. Compared with the manufacturer's solution (PEG, ethanol, water), the cellular uptake is strongly reduced. However, the HT29 phototoxicity is much less affected and a protecting effect against plasma proteins is observed. Fluorescence microscopy reveals a specific punctate fluorescence pattern with PLA-PEG and polox PLA NCs in contrast to a more diffuse distribution with NE and solution, indicating that photodamage targeting could be different. These findings suggest that photosensitizers encapsulated into surface-modified nanocapsules could be a promising approach for improving PDT efficacy and this has to be confirmed in vivo.
Bourdon
O
O
LPBC, UPRESA CNRS 7033 and Université Pierre et Marie Curie, Paris, France.
Mosqueira
V
V
Legrand
P
P
Blais
J
J
D000818:Animals; D001692:Biological Transport; D002214:Capsules; D002460:Cell Line; D003102:Colloids; D004337:Drug Carriers; D019073:HT29 Cells; D006801:Humans; D007773:Lactates; D019344:Lactic Acid; D008264:Macrophages; D008652:Mesoporphyrins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D051379:Mice; D009821:Oils; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D020442:Poloxamer; D011091:Polyesters; D011092:Polyethylene Glycols; D011108:Polymers; D014867:Water
D002214:Capsules; D003102:Colloids; D004337:Drug Carriers; D007773:Lactates; D008652:Mesoporphyrins; D009821:Oils; D017319:Photosensitizing Agents; D011091:Polyesters; D011108:Polymers; C088513:poly(lactic acid-ethylene glycol); D014867:Water; D020442:Poloxamer; D019344:Lactic Acid; D011092:Polyethylene Glycols; C033616:poly(lactide); C072269:temoporfin